Geode Capital Management
HRTX icon

Geode Capital Management’s Heron Therapeutics HRTX Stock Holding History

Geode Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Buy
4,270,980
+260,893
+7% +$209K ﹤0.01% 3210
2026
Q1 		$3.21M Sell
4,010,087
-71,135
-2% -$82.4K ﹤0.01% 2941
2025
Q4 		$5.31M Buy
4,081,222
+438,240
+12% +$541K ﹤0.01% 2733
2025
Q3 		$4.59M Buy
3,642,982
+76,169
+2% +$121K ﹤0.01% 2826
2025
Q2 		$7.38M Buy
3,566,813
+453,085
+15% +$925K ﹤0.01% 2534
2025
Q1 		$6.85M Buy
3,113,728
+98,401
+3% +$191K ﹤0.01% 2506
2024
Q4 		$4.61M Sell
3,015,327
-30,034
-1% -$48.7K ﹤0.01% 2785
2024
Q3 		$6.06M Sell
3,045,361
-66,974
-2% -$160K ﹤0.01% 2660
2024
Q2 		$10.9M Buy
3,112,335
+316,216
+11% +$971K ﹤0.01% 2273
2024
Q1 		$7.75M Buy
2,796,119
+171,445
+7% +$431K ﹤0.01% 2474
2023
Q4 		$4.46M Buy
2,624,674
+229,513
+10% +$253K ﹤0.01% 2764
2023
Q3 		$2.47M Buy
2,395,161
+340,735
+17% +$485K ﹤0.01% 2998
2023
Q2 		$2.38M Buy
2,054,426
+79,472
+4% +$142K ﹤0.01% 3055
2023
Q1 		$2.98M Buy
1,974,954
+16,512
+0.8% +$41.3K ﹤0.01% 2859
2022
Q4 		$4.9M Buy
1,958,442
+132,143
+7% +$426K ﹤0.01% 2678
2022
Q3 		$7.71M Buy
1,826,299
+13,665
+0.8% +$53.5K ﹤0.01% 2426
2022
Q2 		$5.06M Buy
1,812,634
+168,274
+10% +$676K ﹤0.01% 2694
2022
Q1 		$9.4M Sell
1,644,360
-67,248
-4% -$492K ﹤0.01% 2385
2021
Q4 		$15.6M Buy
1,711,608
+99,233
+6% +$1.01M ﹤0.01% 2126
2021
Q3 		$17.2M Buy
1,612,375
+22,983
+1% +$280K ﹤0.01% 2060
2021
Q2 		$24.7M Buy
1,589,392
+148,247
+10% +$2.36M ﹤0.01% 1829
2021
Q1 		$23.4M Buy
1,441,145
+136,474
+10% +$2.43M ﹤0.01% 1775
2020
Q4 		$27.6M Buy
1,304,671
+47,381
+4% +$824K ﹤0.01% 1519
2020
Q3 		$18.6M Sell
1,257,290
-10,896
-0.9% -$170K ﹤0.01% 1588
2020
Q2 		$18.7M Buy
1,268,186
+60,675
+5% +$997K ﹤0.01% 1564
2020
Q1 		$14.2M Buy
1,207,511
+75,251
+7% +$1.41M ﹤0.01% 1518
2019
Q4 		$26.6M Buy
1,132,260
+210,035
+23% +$4.65M 0.01% 1366
2019
Q3 		$17.1M Buy
922,225
+25,145
+3% +$463K ﹤0.01% 1589
2019
Q2 		$16.7M Buy
897,080
+81,852
+10% +$1.64M ﹤0.01% 1606
2019
Q1 		$19.9M Buy
815,228
+63,978
+9% +$1.67M 0.01% 1421
2018
Q4 		$19.5M Buy
751,250
+26,429
+4% +$727K 0.01% 1297
2018
Q3 		$22.9M Buy
724,821
+77,210
+12% +$2.88M 0.01% 1309
2018
Q2 		$25.2M Buy
647,611
+171,911
+36% +$5.47M 0.01% 1188
2018
Q1 		$13.1M Buy
475,700
+78,244
+20% +$1.77M ﹤0.01% 1566
2017
Q4 		$7.19M Buy
397,456
+2,410
+0.6% +$39.3K ﹤0.01% 1981
2017
Q3 		$6.38M Buy
395,046
+8,420
+2% +$132K ﹤0.01% 2047
2017
Q2 		$5.35M Buy
386,626
+26,986
+8% +$391K ﹤0.01% 2104
2017
Q1 		$5.39M Buy
359,640
+95,084
+36% +$1.32M ﹤0.01% 2057
2016
Q4 		$3.46M Buy
264,556
+9,518
+4% +$149K ﹤0.01% 2290
2016
Q3 		$4.39M Buy
255,038
+36,050
+16% +$669K ﹤0.01% 2049
2016
Q2 		$3.95M Buy
218,988
+11,199
+5% +$219K ﹤0.01% 2071
2016
Q1 		$3.94K Buy
207,789
+2,908
+1% +$57.4K ﹤0.01% 2021
2015
Q4 		$5.47M Sell
204,881
-6,125
-3% -$164K ﹤0.01% 1808
2015
Q3 		$5.15M Buy
211,006
+12,956
+7% +$432K ﹤0.01% 1826
2015
Q2 		$6.17M Buy
198,050
+49,270
+33% +$927K ﹤0.01% 1758
2015
Q1 		$2.16M Buy
148,780
+23,296
+19% +$263K ﹤0.01% 2388
2014
Q4 		$1.26M Buy
125,484
+2,017
+2% +$16.5K ﹤0.01% 2704
2014
Q3 		$1.03M Buy
123,467
+13,683
+12% +$127K ﹤0.01% 2761
2014
Q2 		$1.35M Buy
109,784
+47,541
+76% +$568K ﹤0.01% 2613
2014
Q1 		$865K Buy
+62,243
New +$832K ﹤0.01% 2874

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management's HRTX Position: Q2 2026 in Review

Geode Capital Management increased its Heron Therapeutics (HRTX) stake by 6.5% in Q2 2026, buying an estimated $209K and bringing the position to 4,270,980 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3210.

Geode Capital Management first reported a position in HRTX in Q1 2014 and has held it in 50 quarters since. The position peaked at $27.6M in Q4 2020. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Geode Capital Management held 4,270,980 shares of Heron Therapeutics worth $1.82M as of Q2 2026.
  • Geode Capital Management bought 260,893 Heron Therapeutics shares in Q2 2026, an estimated $209K.
  • Heron Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3210 holding.
  • Geode Capital Management first reported a position in Heron Therapeutics in Q1 2014 and has held it in 50 quarters since.
  • Geode Capital Management's Heron Therapeutics position peaked at $27.6M in Q4 2020.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.